Evidence map›Paper›PMID 35016676›Full record

ArticleMalaria journal2022

Comparative efficacy of two pyrethroid-piperonyl butoxide nets (Olyset Plus and PermaNet 3.0) against pyrethroid resistant malaria vectors: a non-inferiority assessment.

Corine Ngufor, Josias Fagbohoun, Abel Agbevo, Hanafy Ismail, Joseph D Challenger, Thomas S Churcher, Mark Rowland

Open access · goldAbstract readComparative Study
In one paragraph

Article in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Bio-efficacy of OlysetTropical medicine and health · 2024
    Article
  16. Article
  17. Behavioural responses ofCurrent research in parasitology & vector-borne diseases · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Corine NguforLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK. corine.ngufor@lshtm.ac.uk.ORCID http://orcid.org/0000-0002-7755-9609
Josias FagbohounCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Abel AgbevoCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Hanafy IsmailLiverpool School of Tropical Medicine, Liverpool, L3 5QA, UK.
Joseph D ChallengerMRC Centre for Global Infectious Disease Analysis, Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, W2 1PG, UK.
Thomas S ChurcherMRC Centre for Global Infectious Disease Analysis, Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, W2 1PG, UK.
Mark RowlandLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK.
Imperial College London · GBLiverpool School of Tropical Medicine · GBLondon School of Hygiene & Tropical Medicine · GBMalaria Consortium · GB

Funding

Medical Research Council MR/L004437/1Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

backgroundPyrethroid-PBO nets were conditionally recommended for control of malaria transmitted by mosquitoes with oxidase-based pyrethroid-resistance based on epidemiological evidence of additional protective effect with Olyset Plus compared to a pyrethroid-only net (Olyset Net). Entomological studies can be used to assess the comparative performance of other brands of pyrethroid-PBO ITNs to Olyset Plus.

methodsAn experimental hut trial was performed in Cové, Benin to compare PermaNet 3.0 (deltamethrin plus PBO on roof panel only) to Olyset Plus (permethrin plus PBO on all panels) against wild pyrethroid-resistant Anopheles gambiae sensu lato (s.l.) following World Health Organization (WHO) guidelines. Both nets were tested unwashed and after 20 standardized washes compared to Olyset Net. Laboratory bioassays were also performed to help explain findings in the experimental huts.

resultsWith unwashed nets, mosquito mortality was higher in huts with PermaNet 3.0 compared to Olyset Plus (41% vs. 28%, P < 0.001). After 20 washes, mortality declined significantly with PermaNet 3.0 (41% unwashed vs. 17% after washing P < 0.001), but not with Olyset Plus (28% unwashed vs. 24% after washing P = 0.433); Olyset Plus induced significantly higher mortality than PermaNet 3.0 and Olyset Net after 20 washes. PermaNet 3.0 showed a higher wash retention of PBO compared to Olyset Plus. A non-inferiority analysis performed with data from unwashed and washed nets together using a margin recommended by the WHO, showed that PermaNet 3.0 was non-inferior to Olyset Plus in terms of mosquito mortality (25% with Olyset Plus vs. 27% with PermaNet 3.0, OR = 1.528, 95%CI = 1.02-2.29) but not in reducing mosquito feeding (25% with Olyset Plus vs. 30% with PermaNet 3.0, OR = 1.192, 95%CI = 0.77-1.84). Both pyrethroid-PBO nets were superior to Olyset Net.

conclusionOlyset Plus outperformed PermaNet 3.0 in terms of its ability to cause greater margins of improved mosquito mortality compared to a standard pyrethroid net, after multiple standardized washes. However, using a margin of non-inferiority defined by the WHO, PermaNet 3.0 was non-inferior to Olyset Plus in inducing mosquito mortality. Considering the low levels of mortality observed and increasing pyrethroid-resistance in West Africa, it is unclear whether either of these nets would demonstrate the same epidemiological impact observed in community trials in East Africa.

Indexed as

Insecticide-Treated BednetsAnimalsAnophelesBeninInsecticide ResistanceMalariaMosquito ControlMosquito VectorsPiperonyl ButoxidePyrethrinsPiperonyl ButoxidePyrethrinsAnophelesBeninCoveCove BeninExperimental hutsInsecticide resistanceInsecticide-treated netsLLINLong-lasting insecticidal netsMixtureNext generation netsOlysetOlyset plusPBOPermaNet 3.0Piperonyl butoxidePyrethroid-PBOPyrethroid resistance

Identifiers

PMID35016676
PMCPMC8753866
OpenAlexW4206342597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.